Anti-acne drugs in phase 1 and 2 clinical trials

References

• Gollnick H, Tan J, Finlay AY. Can we define acne as a chronic disease? Am J Clin Dermatol. 2008;9:279–284.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC. Acne as a chronic systemic disease. Clin Dermatol. 2014;32:389–396.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Jourdan E, Picardo M. Acne as an inflammatory disease and alterations of sebum composition initiate acne lesions. J Eur Acad Dermatol. 2014;28:527–532.
   Web of Science ®Google Scholar
• Moradi Tuchayi S, Makrantonaki E, Ganceviciene R, et al. Acne vulgaris. Nat Rev Dis Primers. 2015;1:15029.
   PubMed Web of Science ®Google Scholar
• Mirdamadi Y, Thielitz A, Wiede A, et al. Insulin and insulin-like growthfactor-1 can modulate the phosphoinositide-3-kinase/Akt/foxO1 pathway in SZ95 sebocytes in vitro. Mol Cell Endocrinol. 2015;415:32–44.
   PubMed Web of Science ®Google Scholar
• Dessinioti C, Katsambas AD. The role of Propionibacterium acnes in acne pathogenesis: facts and controversies. Clin Dermatol. 2010;28:2–7.
   PubMed Web of Science ®Google Scholar
• Shaheen B, Gonzalez M. A microbial aetiology of acne: what is the evidence? Br J Dermatol. 2011;165:474–485.
   PubMed Web of Science ®Google Scholar
• Khorvash F, Abdi F, Kashani HH, et al. Staphylococcus aureus in acne pathogenesis: A case-control study. N Am J Med Sci. 2012;4:573–576.
   PubMedGoogle Scholar
• Numata S, Akamatsu H, Akaza N, et al. Analysis of facial skin-resident microbiota in Japanese acne patients. Dermatology. 2014;228:86–92.
   PubMed Web of Science ®Google Scholar
• Xu DT, Qi XL, Cui Y, et al. Absence or low density of Propionibacterium acnes in comedonal lesions of acne patients? A surface to inside study of skin fluorescence. Exp Dermatol. 2016;25:721–722.
   PubMed Web of Science ®Google Scholar
• Christensen GJ, Scholz CF, Enghild J, et al. Antagonism between Staphylococcus epidermidis and Propionibacterium acnes and its genomic basis. BMC Genomics. 2016;17:152.
   PubMed Web of Science ®Google Scholar
• Thielitz A, Krautheim A, Gollnick H. Update in retinoid therapy of acne. Dermatol Ther. 2006;19:272–279.
   PubMed Web of Science ®Google Scholar
• Thielitz A, Gollnick H. Overview of new therapeutic developments for acne. Expert Rev Dermatol. 2009;4:55–65.
   Google Scholar
• Zouboulis CC, Rabe T. Hormonelle antiandrogene in der aknetherapie. J Dtsch Dermatol Ges. 2010;8(suppl 1):S60–S74.
   PubMed Web of Science ®Google Scholar
• Nast A, Dreno B, Bettoli V, et al. European Evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26(Suppl 1):1–29.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Bettoli V. Management of severe acne. Br J Dermatol. 2015;172(suppl 1):27–36.
   PubMed Web of Science ®Google Scholar
• Tsatsou F, Zouboulis CC. Acne vulgaris. In: Lebwohl MG, Heymann WR, Berth-Jones J, et al., editors. Treatment of skin disease. Comprehensive therapeutic strategies. 4th ed. York: Elsevier Saunders; 2014. p. 6–11.
   Google Scholar
• Dessinioti C, Katsambas A. Propionibacterium acnes and antimicrobial resistance in acne. Clin Dermatol. 2017;35:163–167.
   PubMed Web of Science ®Google Scholar
• Nagy I, Pivarcsi A, Kis K, et al. Propionibacterium acnes and lipopolysaccharide induce the expression of antibacterial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect. 2006;8:2195–2205.
   PubMed Web of Science ®Google Scholar
• Delost GR, Delost ME, Armile J, et al. Staphylococcus aureus carriage rates and antibiotic resistance patterns in patients with acne vulgaris. J Am Acad Dermatol. 2016;74:673–678.
   PubMed Web of Science ®Google Scholar
• Walsh TR, Efthimiou J, Dréno B. Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. Lancet Infect Dis. 2016;16:e23–e33.
   PubMed Web of Science ®Google Scholar
• Margolis DJ, Bowe WP, Hoffstad O, et al. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol. 2005;141:1132–1136.
   PubMed Web of Science ®Google Scholar
• Gollnick HP, Bettoli V, Lambert J, et al. A consensus-based practical and daily guide for the treatment of acne vulgaris. J Eur Acad Dermatol Venereol. 2016;30:1480–1490.
   PubMed Web of Science ®Google Scholar
• Chen W, Obermayer-Pietsch B, Hong JB, et al. Acne-associated syndromes: models for better understanding of acne pathogenesis. J Eur Acad Dermatol Venereol. 2911;25:637–646.
   Google Scholar
• Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? Facts and controversies. Clin Dermatol. 2010;28:17–23.
   PubMed Web of Science ®Google Scholar
• Katsambas A, Dessinioti C. New and emerging treatments in dermatology: acne. Dermatol Ther. 2008;21:86–95.
   PubMed Web of Science ®Google Scholar
• Kelidari HR, Saeedi M, Akbari J, et al. Formulation optimization and in vitro skin penetration of spironolactone loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2015;128:473–479.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Poulin Y, Drew J, et al. Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: a phase IIa, multicentre, randomized, vehicle-controlled study. J Am Acad Dermatol. 2017;76:33–39.
   PubMed Web of Science ®Google Scholar
• Trifu V, Tiplica GS, Naumescu E, et al. Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. Br J Dermatol. 2011;165:177–183.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Angres S, Seltmann H. Regulation of stearoyl-CoA desaturase and fatty acid desaturase 2 expression by linoleic acid and arachidonic acid in human sebocytes leads to enhancement of proinflammatory activity but does not affect lipogenesis. Br J Dermatol. 2011;165:269–276.
   PubMed Web of Science ®Google Scholar
• Meingassner JG, Aschauer H, Winiski AP, et al. Pharmacological inhibition of stearoyl CoA desaturase in the skin induces atrophy of the sebaceous glands. J Invest Dermatol. 2013;133:2091–2094.
   PubMed Web of Science ®Google Scholar
• Bohm M, Ehrchen J, Luger TA. Beneficial effects of the melanocortin analogue Nle4-D-Phe7-α-MSH in acne vulgaris. J Eur Acad Dermatol Venereol. 2014;28:108–111.
   PubMed Web of Science ®Google Scholar
• Ganceviciene R, Bohm M, Fimmel S, et al. The role of neuropeptides in the multifactorial pathogenesis of acne vulgaris. Dermatoendocrinology. 2009;1:170–176.
   PubMedGoogle Scholar
• Zhang L, Li WH, Anthonavage M, et al. Melanocortin-5 receptor and sebogenesis. Eur J Pharmacol. 2011;660:202–206.
   PubMed Web of Science ®Google Scholar
• Eisinger M, Li WH, Anthonavage M, et al. A melanocortin 1 and 5 antagonist inhibits sebaceous gland differentiation and the production of sebum-specific lipids. J Dermatol Sci. 2011;63:23–32.
   PubMed Web of Science ®Google Scholar
• Mastrofrancesco A, Kokot A, Eberle A, et al. KdPT, a tripeptide derivative of alpha-melanocyte-stimulating hormone, suppresses IL-1 beta-mediated cytokine expression and signalling in human sebocytes. J Immunol. 2010;185:1903–1911.
   PubMed Web of Science ®Google Scholar
• Dozsa A, Dezso B, Toth BI, et al. PPARγ-mediated and arachidonic acid-dependent signaling is involved in differentiation and lipid production of human sebocytes. J Invest Dermatol. 2014;134:910–920.
   PubMed Web of Science ®Google Scholar
• Rubinchik E, Dugourd D, Algara T, et al. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrob Agents. 2009;34:457–461.
   PubMed Web of Science ®Google Scholar
• Shemer A, Shiri J, Masbiab J, et al. Topical minocycline foam for moderate to severe acne vulgaris: phase 2 randomized double-blind, vehicle controlled study results. J Am Acad Dermatol. 2016;74:1251–1252.
   PubMed Web of Science ®Google Scholar
• Sinnya S, Tan JM, Prow TW, et al. A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis. Br J Dermatol. 2016;174:305–311.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Seltmann H, Abdel-Naser MB, et al. Effects of extracellular calcium and 1,25 dihydroxyvitamin D3 on sebaceous gland cells in vitro and in vivo. Acta Derm Venereol. 2017;97:313–320.
   PubMed Web of Science ®Google Scholar
• Semprini A, Braithwaite I, Corin A, et al. Randomised controlled trial of topical Kanuka honey for the treatment of acne. BMJ Open. 2016;6:e009448.
   PubMed Web of Science ®Google Scholar
• Richter C, Trojahn C, Hillmann K, et al. Reduction of inflammatory and noninflammatory lesions with topical tyrothricin 0.1% in the treatment of mild to severe acne papulopustulosa: a randomized controlled clinical trial. Skin Pharmacol Physiol. 2016;29:1–8.
   PubMed Web of Science ®Google Scholar
• Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol. 2001;116:793–800.
   PubMed Web of Science ®Google Scholar
• Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism – Basic research and clinical perspectives. J Invest Dermatol. 2002;119:992–1007.
   PubMed Web of Science ®Google Scholar
• Samson M, Labrie F, Zouboulis CC, et al. Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as an intermediate in the SZ95 sebaceous gland cell line. J Invest Dermatol. 2010;130:602–604.
   PubMed Web of Science ®Google Scholar
• Kohler C, Tschumi K, Bodmer C, et al. Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol. 2007;23:142–145.
   PubMed Web of Science ®Google Scholar
• Motofei IG, Rowland DL, Georgescu SR, et al. Finasteride adverse effects in subjects with androgenic alopecia: a possible therapeutic approach according to the lateralization process of the brain. J Dermatol Treat. 2016;27:495–497.
   PubMed Web of Science ®Google Scholar
• Kuźma-Mroczkowska E, Skrzypczyk P, Pańczyk-Tomaszewska M. Levamisole therapy in children with frequently relapsing and steroid-dependent nephrotic syndrome: a single-center experience. Cent Eur J Immunol. 2016;41:243–247.
   PubMed Web of Science ®Google Scholar
• Ansarin H, Savabynasab S, Behzadi AH, et al. Doxycycline plus levamisole: combination treatment for severe nodulocystic acne. J Drugs Dermatol. 2008;7:737–740.
   PubMed Web of Science ®Google Scholar
• Rassai S, Mehri M, Yaghoobi R, et al. Superior efficacy of azithromycin and levamisole vs. azithromycin in the treatment of inflammatory acne vulgaris: an investigator blind randomized clinical trial on 169 patients. Int J Clin Pharmacol Ther. 2013;51:490–494.
   PubMed Web of Science ®Google Scholar
• Hasibur MR, Meraj Z. Combination of low-dose isotretinoin and pulsed oral azithromycin for maximizing efficacy of acne treatment. Mymensingh Med J. 2013;22:42–48.
   PubMedGoogle Scholar
• Ullah G, Noor SM, Bhatti Z, et al. Comparison of oral azithromycin with oral doxycycline in the treatment of acne vulgaris. J Ayub Med Coll Abbottabad. 2014;26:64–67.
   PubMedGoogle Scholar
• Mohammed MY, Mikhael EM. Serratiopeptidase a hope in a rapid and better improvement of inflammatory acne vulgaris. Iraqi J Pharm Sci. 2012;21:78–81.
   Google Scholar
• Nakatsuji T, Liu Y-T, Huang C-P, et al. Antibodies elicited by inactivated Propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris. J Invest Dermatol. 2008;128:2451–2457 (Erratum: 2009;129:1590).
   PubMed Web of Science ®Google Scholar
• Nakatsuji T, Liu Y-T, Huang C-P, et al. Vaccination targeting a surface sialidase of P. acnes: implication for new treatment of acne vulgaris. Plos One. 2008;3:e1551 (Erratum: http://www.plosone.org/corrections/pone.0001551.cn.pdf).
   PubMed Web of Science ®Google Scholar
• Yen T, Yuan C-Y, Huang C-M. Current status of acne vaccines. Expert Rev Dermatol. 2010;5:561–566.
   Google Scholar
• Li ZJ, Choi DK, Sohn KC, et al. Propionibacterium acnes activates the NLRP3 inflammasome in human sebocytes. J Invest Dermatol. 2014;134:2747–2756.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC. Is acne vulgaris a genuine inflammatory disease? Dermatology. 2001;203:277–279.
   PubMed Web of Science ®Google Scholar
• Lee D-Y, Yamasaki K, Rudsil J, et al. Sebocytes express functional cathelicidin antimicrobial peptides and can act to kill Propionibacterium acnes. J Invest Dermatol. 2008;128:1863–1866.
   PubMed Web of Science ®Google Scholar
• Kanada KN, Nakatsuji T, Gallo RL. Doxycyline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012;132:1435–1442.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Webster GW, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791–802.
   PubMed Web of Science ®Google Scholar
• Moore A, Ling M, Bucko A, et al. Efficacy and safety of subantimicrobial dose, modified-release doxycycline 40 mg versus doxycycline 100 mg versus placebo for the treatment of inflammatory lesions in moderate and severe acne: a randomized, double-blinded, controlled study. J Drugs Dermatol. 2015;14:581–586.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC. Leukotrien-antagonisten bei atopischen erkrankungen und akne. Akt Dermatol. 2003;29:419–425.
   Google Scholar
• Alestas T, Ganceviciene R, Fimmel S, et al. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med. 2006;84:75–87.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Seltmann H, Alestas T. Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis. Exp Dermatol. 2010;19:148–150.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC. Zileuton, a new efficient and safe systemic anti-acne drug. Dermatoendocrinol. 2009;1:188–192.
   PubMedGoogle Scholar
• Zouboulis CC, Saborowski A, Boschnakow A. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology. 2005;210:36–38.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Nestoris S, Adler YD, et al. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol. 2003;139:668–670.
   PubMed Web of Science ®Google Scholar
• Baert B, De Spiegeleer B. Local skin pharmacokinetics of talarozole, a new retinoic acid metabolism-blocking agent. Skin Pharmacol Physiol. 2011;24:151–159.
   PubMed Web of Science ®Google Scholar
• Geria AN, Scheinfeld NS. Talarozole, a selective inhibitor of P450-mediated all-trans retinoic acid for the treatment of psoriasis and acne. Curr Opin Investig Drugs. 2008;9:1228–1237.
   PubMed Web of Science ®Google Scholar
• Verfaille CJ, Coel M, Boersma IH, et al. Oral R115866 in the treatment of moderate to severe facial acne vulgaris: an exploratory study. Br J Dermatol. 2007;157:122–126.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Seltmann H, Zouboulis CC, et al. Involvement of PPAR-gamma in oxidative stress-mediated prostaglandin E2 production in SZ95 human sebaceous gland cells. J Invest Dermatol. 2006;126:42–48.
   PubMed Web of Science ®Google Scholar
• Thielitz A, Reinhold D, Vetter R. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) target major pathogenetic steps in acne initiation. J Invest Dermatol. 2007;127:1042–1051.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Seltmann H, Hiroi N, et al. Corticotropin releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci USA. 2002;99:7148–7153.
   PubMed Web of Science ®Google Scholar
• Ganceviciene R, Graziene V, Fimmel S, et al. Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris. Br J Dermatol. 2009;160:345–352.
   PubMed Web of Science ®Google Scholar
• Dobrosi N, Tóth BI, Nagy G, et al. Endocannabinoids enhance lipid synthesis in human sebocytes via cannabinoid receptor-2-mediated signaling. Faseb J. 2008;22:3685–3695.
   PubMed Web of Science ®Google Scholar
• Oláh A, Markovics A, Szabó-Papp J, et al. Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry /seborrheic skin and acne treatment. Exp Dermatol. 2016;25:701–707.
   PubMed Web of Science ®Google Scholar
• Oeff MK, Seltmann H, Hiroi N, et al. Differential regulation of Toll-like receptor and CD14 pathways by retinoids and corticosteroids in human sebocytes. Dermatology. 2006;213:266.
   PubMed Web of Science ®Google Scholar
• Huang YC, Yang CH, Li TT, et al. Cell-free extracts of Propionibacterium acnes stimulate cytokine production through activation of p38 MAPK and Toll-like receptor in SZ95 sebocytes. Life Sci. 2015;139:123–131.
   PubMed Web of Science ®Google Scholar
• Antoniou C, Dessinioti C, Stratigos AJ, et al. Clinical and therapeutic approach to childhood acne: an update. Pediatr Dermatol. 2009;26:373–380.
   PubMed Web of Science ®Google Scholar
• Dessinioti C, Dréno B. Acne. In: Katsambas AD, Lotti TM, Dessinioti C, et al., editors. European handbook of dermatological treatments. Berlin: Springer; 2015. p. 3–19.
   Google Scholar
• Dréno B, Layton A, Zouboulis CC, et al. Adult female acne: a new paradigm. J Eur Acad Dermatol. 2013;27:1063–1070.
   Web of Science ®Google Scholar
• Zampeli VA, Makrantonaki E, Tzellos T, et al. New pharmaceutical concepts for sebaceous gland diseases: implementing today’s pre-clinical data into tomorrow’s daily clinical practice. Cur Pharm Biotechnol. 2012;13:1898–1913.
   PubMed Web of Science ®Google Scholar
• Dessinioti C, Zouboulis CC. Concepts of future acne treatments. In: Zouboulis CC, Katsambas AD, Kligman AM, editors. Pathogenesis and treatment of acne and rosacea. Berlin: Springer; 2014. p. 537–542.
   Google Scholar
• Gollnick HPM. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol. 2015;29(suppl 5):1–7.
   Google Scholar